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ARTICLE

Prospective Home-use Study on Non-invasive
Neuromodulation Therapy for Essential Tremor
Stuart H. Isaacson*, Elizabeth Peckham†, Winona Tse‡, Olga Waln§, Christopher Way‖,
Melita T. Petrossian¶, Nabila Dahodwala**, Michael J. Soileau††, Mark Lew‡‡, Cameron
Dietiker§§, Nijee Luthra§§, Pinky Agarwal‖‖, Rohit Dhall¶¶, John Morgan***, Nicole Calakos†††,
Theresa A. Zesiewicz‡‡‡, Ejaz A. Shamim§§§, Rajeev Kumar‖‖‖, Peter LeWitt¶¶¶, Holly A. Shill****,
Adam Simmons††††, Fernando L. Pagan‡‡‡‡, Pravin Khemani§§§§, Jessica Tate‖‖‖‖, Brian Maddux¶¶¶¶,
Lan Luo*****, William Ondo§, Mark Hallett†††††, Apoorva Rajagopal‡‡‡‡‡, Paula Chidester‡‡‡‡‡,
Kathryn H. Rosenbluth‡‡‡‡‡, Scott L. Delp§§§§§ and Rajesh Pahwa‖‖‖‖‖
Highlights
This prospective study is one of the largest clinical trials in essential tremor to date. Study findings suggest
that individualized non-invasive neuromodulation therapy used repeatedly at home over three months results
in safe and effective hand tremor reduction and improves quality of life for many essential tremor patients.
Background: Two previous randomized, controlled, single-session trials demonstrated efficacy of non-invasive
neuromodulation therapy targeting the median and radial nerves for reducing hand tremor. This current study
evaluated efficacy and safety of the therapy over three months of repeated home use.
Methods: This was a prospective, open-label, post-clearance, single-arm study with 263 patients enrolled
across 26 sites. Patients were instructed to use the therapy twice daily for three months. Pre-specified
co-primary endpoints were improvements on clinician-rated Tremor Research Group Essential Tremor Rating
Assessment Scale (TETRAS) and patient-rated Bain & Findley Activities of Daily Living (BF-ADL) dominant
hand scores. Other endpoints included improvement in the tremor power detected by an accelerometer on the
therapeutic device, Clinical and Patient Global Impression scores (CGI-I, PGI-I), and Quality of Life in Essential
Tremor (QUEST) survey.
Results: 205 patients completed the study. The co-primary endpoints were met (p≪0.0001), with 62% (TETRAS) and 68% (BF-ADL) of ‘severe’ or ‘moderate’ patients improving to ‘mild’ or ‘slight’. Clinicians (CGI-I)
reported improvement in 68% of patients, 60% (PGI-I) of patients reported improvement, and QUEST improved
(p = 0.0019). Wrist-worn accelerometer recordings before and after 21,806 therapy sessions showed that
92% of patients improved, and 54% of patients experienced ≥50% improvement in tremor power. Device-related adverse events (e.g., wrist discomfort, skin irritation, pain) occurred in 18% of patients. No device-related serious adverse events were reported.
Discussion: This study suggests that non-invasive neuromodulation therapy used repeatedly at home over
three months results in safe and effective hand tremor reduction in many essential tremor patients.
Keywords: clinical trials; tremor; neuromodulation; stimulation; non-invasive
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Introduction
Essential tremor (ET) is one of the most common movement disorders [1]. Upper limbs are affected in virtually all
ET patients, and other regions (e.g., head, voice, and lower
limbs) are affected in some patients [2, 3]. ET can be physically, psychologically, and socially detrimental, and reduce
the quality of life for patients [4–9]. The mechanisms of
ET are not completely understood, but studies comparing
neural activity, brain imaging, and electromyography data
between ET patients and healthy adults suggest that ET is
caused by rhythmic signaling within a central tremor neural
network involving the ventral intermediate nucleus (VIM) of
the thalamus [10–16].
Current pharmacotherapy options for ET include the use
of nonselective β-blockers (propranolol) and anticonvulsants (primidone) as first-line treatments, and topiramate,
benzodiazepines, gabapentin, zonisamide, and pregabalin
as second-line treatments, but patient responses to these
medications are variable [17–22]. For patients who do not
respond to medications, current alternative options are
invasive neurosurgical procedures, including VIM deep
brain stimulation (DBS), or magnetic resonance-guided
focused ultrasound (MRgFUS) VIM thalamotomy [17, 23].
These second-line options, while effective for many, carry
the significant safety risks and expenses associated with
invasive procedures [24, 25].
Previous research demonstrating that electrical stimulation of peripheral nerves at the wrist evoked activity within
the VIM and other regions of the central tremor network
led to the development of a non-invasive neuromodulation therapy called Transcutaneous Afferent Patterned
Stimulation (TAPS) [26, 27]. TAPS consists of bursts of
non-invasive electrical stimulation alternating between the
median and radial nerves at the wrist at a frequency tuned
to an individual patient’s tremor. Two sham-controlled,
randomized, single-session studies have shown TAPS to be
a safe and effective symptomatic ET treatment [28, 29],
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leading to United States Food and Drug Administration
(FDA) clearance [30, 31]. However, it is unknown how these
single-session findings on TAPS safety and efficacy translate
to longer-term efficacy as the therapy is used at home.
The goal of this study was to expand understanding of
efficacy and safety of TAPS from usage in a single session to
three months of repeated use. Efficacy was measured using
clinical gold standard measurements, patient-reported
outcomes, and objective kinematic tremor physiology endpoints. The study was run without a blinded sham arm due
to the challenge of mimicking the sensation of stimulation
or otherwise maintaining blind with an at-home device over
three months of repeated use.
Methods

Study design and patient population

This study was a prospective, multi-center, single-arm,
open-label clinical trial to evaluate the safety and efficacy
of TAPS therapy over a three-month period. The therapy was
delivered with an FDA-cleared wrist-worn neuromodulation
device (Cala Health, Inc.; Burlingame, CA, USA). The study was
registered as clinical trial (NCT03597100, clinicaltrials.gov)
entitled Prospective Study for Symptomatic Relief of ET
with Cala Therapy (PROSPECT). The study included three
in-clinic visits: Visit 1 (patient screening and enrollment),
Visit 2 (1-month follow-up), and Visit 3 (3-month follow-up
and study completion). Between these visits, patients took
the device home and were instructed to use the TAPS therapy
twice daily (Figure 1A). The study protocol was approved by
Institutional Review Boards for each participating site, and
informed consent was obtained from each patient.
To be eligible for this study, patients had to have been previously diagnosed with ET by a physician, be ≥22 years of age,
have at least one dominant hand task scoring ≥2 on the clinician-rated Tremor Research Group Essential Tremor Rating
Assessment Scale (TETRAS) [32] and ≥3 on the self-rated Bain
& Findley Activities of Daily Living (BF-ADL) [33], and have a
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Figure 1: Study design, therapeutic device, and calibration postures. (A) The study included 3 in-clinic visits over 3
months with interim prescribed twice-daily home-use of therapy. (B) The wrist-worn device consisted of a stimulator,
detachable band, and base station. The stimulator applied the stimulation pattern to the band and had an onboard
triaxial accelerometer to measure tremor. The band contained two working electrodes positioned over the median and
radial nerves and a counter-electrode positioned on the dorsal side of the wrist. The base station streamed accelerometer
and usage data daily and charged the device. (C) Patients performed either a lateral or forward postural hold for device
calibration and for tremor measurement pre- and post-stimulation.
total score across all dominant hand tasks ≥6 on TETRAS and
≥8 on BF-ADL. The six TETRAS dominant hand tasks assessed
were (1) forward outstretched postural, (2) lateral postural, (3)
kinetic, (4) spiral, (5) handwriting, and (6) dot approximation,
with each task rated on a scale of 0 (“no tremor”), 1 (“slight,
barely noticeable tremor; <0.5 cm amplitude”), 2 (“mild, obvious tremor; <3 cm”), 3 (“moderate, portions of drawing or
writing not legible; <10 cm”), to 4 (“severe, drawing or writing
complete illegible; ≥10 cm”) [32]. The eight BF-ADL dominant hand tasks assessed were (1) use a spoon to drink soup,
(2) hold a cup of tea, (3) pour milk from a bottle, (4) dial a
telephone, (5) pick up change, (6) insert an electric plug, (7)
unlock front door, and (8) write a letter, with each task performed using in-office props and rated on a scale of 1 (“able
to do without difficulty”), 2 (“able to do with little effort”),
3 (“able to do with a lot of effort”), to 4 (“cannot do without
assistance”) [33]. If a patient was on medication to treat
tremor, medication dosage had to be unchanged for at least
30 days prior to enrollment. Exclusion criteria included prior
DBS, prior thalamotomy, epilepsy, skin lesions or eruptions at
the targeted stimulation site, neuropathy of the tested upper
extremity, any neurodegenerative disease aside from tremor,
use of botulinum toxin for treatment of hand tremor within
six months of enrollment, pregnancy, and significant alcohol
or caffeine intake within 8 hours before enrollment.
Device description, calibration, and usage

Patients were treated with a wrist-worn TAPS neuromodulation device that consisted of an electrical stimulator and

a detachable band with two working electrodes positioned
over the median and radial nerves and a counter-electrode
positioned on the dorsal side of the wrist (Figure 1B). For
each TAPS therapy session, the device electrically stimulated the median and radial nerves for 40 minutes with an
alternating bursting pattern tuned to the frequency of each
patient’s tremor (details below) [29]. The device included
an onboard accelerometer to measure tremor physiology,
and a base station that charged the device and streamed the
device data to a centralized study database.
At Visit 1, study personnel fitted patients with a small,
medium, or large band according to the patient’s wrist circumference, and helped patients set up the device. To calibrate the device’s bursting frequency, patients performed a
series of 20-second postural holds to measure their tremor
frequency (Figure 1C). For this calibration, patients performed either a forward outstretched or lateral postural
hold, based on whichever was more severe. To set the
stimulation intensity, study personnel gradually increased
the stimulation until the patient reported paresthesia in
the hand and fingers corresponding to the distribution of
the median and radial nerves. The stimulation was then
further increased to the maximum level that caused no discomfort or muscle contraction. Thereafter, at the start of
each therapy session, the device ramped to this stimulation
level and provided therapy for 40 minutes. Patients had the
option to adjust the stimulation level at any time.
Patients received therapy sessions at each of the three
in-clinic visits and were instructed to use the device at home
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twice daily for three months. They were instructed to perform the home therapy sessions at least 2 hours apart and to
refrain from alcohol, caffeine, and device usage for at least
8 hours prior to the in-clinic visits. Immediately prior to and
following each therapy session, the device prompted users
to perform the postural hold used to calibrate the device
at Visit 1 for 20 seconds, and the device’s accelerometer
measured the tremor. Additionally, immediately prior to
and following each of the three in-clinic therapy sessions,
a clinician rated patients on TETRAS task performance and
patients self-rated BF-ADL task performance using available
in-office props.
Co-primary endpoint analyses

The pre-specified co-primary efficacy endpoints were
improvement in total: (1) clinician-rated TETRAS dominant
hand score, and (2) patient-rated BF-ADL dominant hand
score. For each scale, the improvement was defined as the
difference between the pre-stimulation score at Visit 1 and
the post-stimulation score at Visit 3. The co-primary endpoints were analyzed for all patients who completed their
third in-clinic visit.
The TETRAS dominant hand scores were further classified
consistently with the 0 to 4-point TETRAS scale as either
‘No tremor’ (total score of 0), ‘Slight’ (1–6), ‘Mild’ (7–12),
‘Moderate’ (13–18), or ‘Severe’ (19–24). These categories
correspond to having an average TETRAS score across the
six assessed tasks of 0 (‘no tremor’), >0–1 (‘Slight’), >1–2
(‘Mild’), >2–3 (‘Moderate’), and >3–4 (‘Severe’). Similarly, the
BF-ADL dominant hand scores were classified as either ‘No
tremor’ (total score of 8), ‘Mild’ (9–16), ‘Moderate’ (17–24),
or ‘Severe’ (25–32), which correspond to having an average
score across the eight assessed tasks of 1 (“able to do without
difficulty), >1–2 (“able to do with little effort”), >2–3 (“able
to do with a lot of effort”), and >3–4 (“cannot do without
assistance”) on the 1 to 4-point ADL scale.
Changes in each of the following were tested with a
2-sided t-test: (1) the co-primary endpoints, (2) TETRAS
and BF-ADL scores from pre- to post-stimulation at each of
the three in-clinic visits, and (3) TETRAS and BF-ADL scores
from pre-stimulation at Visit 1 to pre-stimulation at Visit
3. Changes in severity classifications (i.e., ‘Mild’ – ‘Severe’)
from the Visit 1 pre-stimulation to Visit 3 post-stimulation
assessments were summarized as the percentage of patients
in each category. Total and per-task TETRAS and BF-ADL
scores were summarized using measures of central tendency
and variance.
Secondary endpoint analysis

The secondary efficacy endpoint was defined as the improvement in tremor power between the pre- and post-stimulation
postural holds, as measured by the device’s accelerometer.
During each 20-second postural hold, wrist acceleration
data were collected at a sampling frequency of 104 Hz. The
first and last 4 seconds of these data were excluded to avoid
transitions in and out of the postures. The algorithm to
compute tremor power included six steps: (1) separating the
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remaining 12-second signal into five 2.4-second nonoverlapping segments, (2) computing the power spectral density
(PSD) for each segment using a fast Fourier transform
(scipy.org, fft) with a 256-sample Hann window, (3) identifying frequency of the peak tremor power in the 4–12 Hz
band typically associated with ET, (4) computing the integral
of the PSD for each of the three accelerometer axes in the
±1.2 Hz frequency window centered on frequency identified
in step 3, (5) summing over the three axes, and (6) averaging
these results over the segments.
The change in each patient’s pre- and post-stimulation
tremor power was defined as the median change over all
valid stimulation sessions. Valid sessions were defined as
all sessions with a complete 40-minutes of stimulation,
pre- and post-stimulation measurement occurring within
15 minutes of the stimulation start or end, and at least 2
hours of time elapsed since the previous session. A Wilcoxon
signed-rank test was used to test for a change from the preto post-stimulation tremor power.
The improvement ratio for each patient was defined as the
median of the ratios of pre- to post-stimulation tremor power
over all valid sessions. With this definition, an improvement
ratio of 1 indicates that tremor power was unchanged from
pre- to post-stimulation, a ratio >1 indicates that tremor
power improved (i.e., decreased) from pre- to post-stimulation, and a ratio <1 indicates that tremor power worsened
(i.e., increased) from pre- to post-stimulation.
To compare the clinical TETRAS tremor severity ratings
with the objective physiologic measurements of tremor
power, at the first clinic visit patients performed three postural holds during which the device measured wrist acceleration and clinicians simultaneously provided TETRAS
ratings. The association between the average TETRAS rating
and the log10-transformed average tremor power was quantified using the Pearson correlation coefficient [34].
Safety endpoints

Device safety was evaluated by the incidence of device- and
therapy-related adverse events (AEs). These data were summarized using frequency counts and percentages.
Exploratory analyses

Exploratory analyses included evaluating Clinical and
Patient Global Impression of Improvement (CGI-I, PGI-I,
respectively) scores, assessed at the study’s conclusion, and
change in the average domain score of Quality of Life in
Essential Tremor Questionnaire (QUEST) from the start to
conclusion of the study [35–37]. CGI-I and PGI-I scores were
summarized using response percentages, and QUEST was
tested for change using a 2-sided t-test.
To assess the effect of concurrent ET medication usage on
treatment efficacy, the statistical comparisons evaluating
co-primary and secondary endpoints were repeated for the
on-medication and off-medication patient sub-groups.
To assess device usability, patients were asked to complete
a product survey rating convenience and ease-of-use of the
device. To assess the duration of therapeutic effect, patients
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were asked “Did tremor relief last after a stimulation dose?”
and, if they answered yes, were asked “On average, how long
did tremor relief last after a stimulation dose?”.
Significance testing

All reported p-values have been adjusted using Holm-Bonferroni corrections [38] for multiple comparisons. Significance for all analyses was set at p < 0.05 after corrections.
Unless otherwise specified, outcome statistics are reported
as mean ± 1 standard error.
Results

Study enrollment and completion

The study enrolled 263 patients across 26 sites (Table 1). 205
of the 263 enrolled patients completed their third in-clinic
visit and were included in the primary endpoint analysis.

Table 1: Enrolled patient demographics (N = 263).
Demographics
Female

52% (137)

Age

69.6 ± 10.1 (23–89)

BMI

28.2 ± 5.4 (16–48)

Race
Asian

4% (11)

Black or African American

3% (7)

White

90% (237)

More than one race

1% (3)

Unknown or not reported

2% (5)

Ethnicity
Hispanic or Latino

3% (7)

Not Hispanic or Latino

96% (253)

Unknown or not reported

1% (3)

Discontinuations included withdrawal of consent (n = 27),
adverse events (n = 8), investigator decision (n = 1), failure
to complete Visit 3 procedures (n = 9), and other reasons
(n = 13). Reasons cited for withdrawal from the study included
time commitment, lack of benefit, device malfunctions, fear
of AE reoccurrence, falling out of eligibility criteria, dislike of
stimulation sensation, and other or unspecified reasons.
On average, these 205 patients completed at least
one stimulation session per day for 78% of the days they
were enrolled in the study and completed 68% of their
total instructed (i.e., twice-daily) stimulation sessions (see
Supplemental Figure 1 for distribution of stimulation session adherence). 193 of these 205 patients completed a
total of 21,806 valid stimulation sessions at home and were
included in the secondary endpoint analysis. 10 patients
were excluded due to errors with the accelerometer recordings, 2 patients were excluded due to incorrect device calibration, and 1,808 stimulation sessions from the remaining
193 patients were excluded due to missing valid pre- and/or
post-stimulation measurements.
Co-primary outcomes

TETRAS and BF-ADL dominant hand scores improved
from baseline to study exit (i.e., Visit 1 pre-stimulation
to Visit 3 post-stimulation; Table 2, Figure 2). Patients
showed improvement in TETRAS and BF-ADL from pre- to
post-stimulation at each in-clinic visit (p ≪ 0.0001 for all six
pairs; Figure 2). Additionally, pre-stimulation tremor level
improved from Visit 1 to Visit 3 on both TETRAS and BF-ADL
(p ≪ 0.0001 for both) (Figure 2).
The proportion of patients rated “Severe” or “Moderate”
improved from 49.3% (TETRAS) and 64.8% (BF-ADL) at
baseline (Visit 1 pre-stimulation) to 21.0% (TETRAS) and
23.0% (BF-ADL) at study exit (Visit 3 post-stimulation;
Figure 3A). While the magnitude of improvement varied
between patients (see Supplemental Figure 2 for distribution of TETRAS and BF-ADL improvements), 62% of patients
with a “Severe” or “Moderate” TETRAS score (score between

Clinical Characteristics
Onset Age

43.9 ± 20.4 (2–79)

ET Duration

25.6 ± 18.1 (1–76)

Table 2: Descriptive statistics of co-primary and secondary
endpoints.

Family History
Yes

62% (163)

No

27% (71)

Don’t Know

11% (29)

On ET Medications
On Antidepressant Medications

66% (173)
14% (36)

Baseline Final visit
Mean (SD) Mean (SD)
Co-primary endpoints1
TETRAS dominant
hand score2

12.6 (2.7)

9.8 (3.5)

–2.8 (2.8)*

BF-ADL dominant
hand score3

18.4 (3.8)

13.4 (4.4)

–5.0 (4.3)*

1.1 (4.4)

0.3 (1.1)

–0.8 (3.7)*

Prior ET Treatment (Any)

78% (206)

Secondary endpoint4

Prior ET Medications

78% (205)

Tremor power (m/s2)2

Prior Botulinum
Responsive to Alcohol
Reported as % patients (#) or mean ± SD (min – max).

4% (11)
37% (96)

Change
Mean (SD)

* p ≪ 0.0001 after Holm-Bonferroni corrections for multiple hypothesis testing.
1
n = 205; 2 Minimum score 0, maximum score 24; 3 Minimum score
8, maximum score 32; 4 n = 193.
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Figure 2: Co-primary endpoints assessed in-clinic showed improvement in TETRAS and BF-ADL. Average TETRAS
dominant hand score (left, scale range 0–24) and BF-ADL dominant hand score (right, scale range 8 to 32) are shown
pre- and post-stimulation conducted at each in-clinic visit. The co-primary TETRAS and BF-ADL endpoints—improvement
from baseline (pre-stimulation rating at Visit 1) to study exit (post-stimulation rating at Visit 3)—were both met (n = 205).
Therapeutic response was also significant within each visit for both TETRAS and BF-ADL, and the pre-stimulation tremor
rating improved significantly over 3 months of use. Error bars represent ±1 SEM, and * indicates p < 0.0001.

Figure 3: Tremor severity distributions shifted towards milder tremor at study exit. (A) The distribution of tremor
severity at the time of co-primary endpoints (i.e., Visit 1 pre-stimulation to Visit 3 post-stimulation) were assessed for TETRAS (left) and BF-ADL (right). On both scales, the distribution of tremor severity shifted towards milder tremor. (B) Study
exit (Visit 3 post-stimulation) tremor severity distributions were broken down for each baseline severity group for TETRAS
(left) and BF-ADL (right). Most patients improved in tremor severity relative to their baseline or stayed in the same severity
classification, with more severe patients showing greater improvement. Severity categories were defined consistent with
TETRAS guidelines.
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13 and 24) improved to “Mild” or better (score ≤ 12), and
68% of patients with a “Severe” or “Moderate” BF-ADL score
improved to “Mild” or better (score ≤ 16; Figure 3B). Only a
small number of patients worsened in severity category (5
for TETRAS, 6 for BF-ADL; Figure 3B) or improved in severity category with a ≤1-point change in score (3 for TETRAS,
1 for BF-ADL).
Per-task improvements from baseline to study exit showed
that on any rated task, between 58%–80% (TETRAS) and
61%–76% (BF-ADL) of patients who were rated as at least
“Mild” improved at least one rating-increment on the task’s
scale (Table 3). Per-task improvements were variable and
responder rates were lower (between 45%–74%) among the
full study population due to ceiling effects on improvement
of patients scoring below “Mild” on each task (Supplemental
Table 1; right columns).
Secondary outcomes

Tremor power improved during home use, with the mean
tremor power over all patients decreasing from 1.1 ± 0.3
(m/s2)2 pre-stimulation to 0.3 ± 0.1 (m/s2)2 post-stimulation
(p ≪ 0.0001) (Table 2; Figure 4A). The log10-tremor power
was correlated to the simultaneously measured TETRAS ratings (r = 0.67, p ≪ 0.0001) (Figure 4B), with equation (1)
describing the mathematical relationship.

log10  Tremor Power  
1.26  TETRAS  3.13 (1)

A sample raw acceleration trace corresponding to a 9-fold
reduction (i.e., strong therapeutic response) in tremor
power from pre- to post-stimulation is shown for illustrative purposes (Figure 4C). Overall, daily usage of the device
resulted in a median improvement in tremor power over all
stimulation sessions for 92% of patients (Figure 4D). 54%
of patients had a ≥2 improvement ratio in tremor power
(i.e., post-tremor power ≤½ pre-tremor power, or 50%
reduction in pre-tremor power), and 25% of patients had a
≥3.3 improvement ratio (70% reduction) in tremor power.
Safety outcomes

No device-related serious AEs were reported. Non-serious
device-related AEs occurred in 18% patients. The most
common device-related AEs were persistent skin irritation
(5% patients), sore/lesion (4% patients), discomfort (2%
patients), electrical burns (2% patients), and minor skin irritation including itchiness or redness (2% patients) (Table 4).
64% of the reported device-related AEs were rated by the
clinical investigator as “Mild” (e.g., itchiness, discomfort),
34% as “Moderate” (e.g., electrical burns, significant discomfort), and 2% (1 event) as “Severe” (a fall, that was possibly
device-related). All device-related AEs were resolved either

Table 3: Co-primary outcomes by task.
Patient count
per task1

Baseline
Mean (SD)

Final visit
Mean (SD)

Change
Mean (SD)

% Patients
improved2

Forward Outstretched

124

2.2 (0.3)

1.5 (0.6)

–0.6 (0.6)*

78%

Lateral

140

2.3 (0.4)

1.7 (0.7)

–0.6 (0.6)*

80%

Kinetic

163

2.3 (0.4)

1.7 (0.6)

–0.6 (0.5)*

79%

Spiral

161

2.5 (0.7)

2.0 (0.8)

–0.5 (0.8)*

58%

Handwriting

144

2.8 (0.7)

2.0 (1.0)

–0.8 (0.8)*

67%

155

2.4 (0.5)

1.9 (0.7)

–0.4 (0.6)*

66%

Use a spoon to drink soup

196

2.9 (0.6)

2.0 (0.9)

–0.9 (0.8)*

70%

Hold a cup of tea

192

2.8 (0.7)

1.8 (0.9)

–1.0 (0.9)*

71%

Pour milk from a bottle

182

2.8 (0.7)

1.8 (0.9)

–1.0 (0.9)*

69%

Dial a telephone

131

2.6 (0.7)

1.8 (0.9)

–0.8 (0.8)*

76%

Pick up change

134

2.6 (0.7)

1.8 (0.9)

–0.8 (0.8)*

69%

Insert an electric plug

134

2.4 (0.5)

1.5 (0.6)

–0.9 (0.8)*

69%

Unlock front door

148

2.4 (0.5)

1.5 (0.6)

–0.9 (0.8)*

72%

Write a letter

192

2.3 (0.5)

1.5 (0.7)

–0.8 (0.8)*

61%

TETRAS Tasks3

Dot Approximation
BF-ADL Tasks

4

* p ≪ 0.0001 after Holm-Bonferroni corrections for multiple hypothesis testing.
1
Count of patients scoring at least “Mild” per task (2 on TETRAS or BF-ADL).
2
Defined as % patients improving at least one increment (0.5 or 1, depending on scale and task).
3
Each TETRAS task rated 0–4 by clinician (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe).
4
Each BF-ADL task rated 1–4 by patient (1 = without difficulty, 2 = with a little effort, 3 = with a lot of effort, 4 = cannot do by yourself).
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Figure 4: Secondary endpoint from at-home accelerometer measures show improvement in tremor physiology
with therapy. (A) Average tremor power decreased from pre-stimulation to post-stimulation (data represents 193
patients and 21,806 total sessions). Error bars represent ±1 SEM, and * indicates p < 0.0001. (B) Tremor power, computed
from the triaxial acceleration signals, was correlated to the clinician-rated TETRAS postural hold rating (r = 0.67, p <
0.0001). (C) Example 3-second segment of the wrist acceleration time series along one of the three accelerometer axes
with corresponding tremor power measures are shown for a single session before and after stimulation. (D) 92% of all
patients had an improvement ratio > 1, indicating an improvement in tremor power from pre- to post-stimulation. Each
bar represents a single-patient’s median improvement in tremor power from pre- to post-stimulation over all at-home
stimulation sessions over three months (n = 193 patients).

Table 4: Device-related adverse events.
Adverse Event Type1

% Subjects (#)

# Events

17.9% (47)

56

Significant and persistent skin irritation (including redness, itchiness, and/or swelling)

5.3% (14)

15

Sore/Lesion

3.8% (10)

11

Significant discomfort

2.3% (6)

7

Electrical burns

2.3% (6)

6

Other: minor skin irritation (including itchiness and/or redness)

2.3% (6)

6

Other: electric shock sensation while using device

1.1% (3)

3

Other: worsening of tremor

0.8% (2)

2

Other isolated events

2.0% (5)

6

All

2

1
2

Rated by investigator to be possibly, probably or definitely device-related.
Each of the following occurred in only one patient: fall, anxiety, intermittent soreness in treated wrist, weakness or lack of coordination
in treated hand, persistent pain from stimulation.

Isaacson et al: Non-invasive Therapy for Essential Tremor

Art. 29, page 9 of 16

Figure 5: Clinical and Patient Global impression of improvement (C/PGI-I). Clinicians and patients were surveyed
with the 7-point global impression scale of improvement at Visit 3 post the in-clinic stimulation session to assess
improvements in dominant hand tremor relative to baseline. Clinicians (CGI-I) and patients (PGI-I) reported hand tremor
minimally, much or very much improved in 68% and 60% of patients, respectively.
without intervention, with decreasing stimulation amplitude, with a topical ointment such as aloe vera or hydrocortisone cream, or by discontinuing therapy until resolved.
There was only one report of minor sequelae that occurred
in a patient with pre-existing psoriasis. There were 6 withdrawals due to device-related AEs, of which 3 were due to
skin irritation and 3 were due to discomfort, anxiety, and
tremor worsening.
Exploratory outcomes

After three months of use, clinicians reported tremor
improvement in 68% of patients (15% much improved or
very much improved; CGI-I) and 60% of patients self-reported improvement (27% much improved or very much
improved; PGI-I) (Figure 5). In QUEST surveys conducted
after three months of use, patients indicated their quality of
life improved (–3.1 ± 0.9 change in QUEST average domain
score, p = 0.0019). Among the QUEST domains, physical
domain improved the most (–6.3 ± 1.2, p ≪ 0.0001), followed by work and finance domains (–3.6 ± 1.1, p = 0.0015).
The therapy was effective for patients, regardless of concurrent ET medication usage. Patients off ET medication
(n = 66) improved by 3.2 ± 0.3 points on TETRAS (p ≪
0.0001) and 5.3 ± 0.5 points on BF-ADL (p ≪ 0.0001) from
pre-stimulation Visit 1 to post-stimulation Visit 3. Patients
on ET medication (n = 139) improved by 2.6 ± 0.2 points
on TETRAS (p ≪ 0.0001) and 4.8 ± 0.4 points on BF-ADL
(p ≪ 0.0001) from pre-stimulation Visit 1 to post-stimulation Visit 3. Similarly, tremor power decreased from 1.40 ±
0.74 pre-stimulation to 0.25 ± 0.10 post-stimulation (p ≪
0.0001) for patients off medication (n = 65), and from 0.91 ±
0.30 to 0.28 ± 0.11 (p ≪ 0.0001) for patients on medication
(n = 128). The improvements in TETRAS, BF-ADL, and tremor
power were not statistically different between the patients
off- and on-medication.

On patient surveys, 85% of patients reported that the
device was convenient and easy to use, and 64% of patients
reported persistent tremor relief after the 40 minutes of
stimulation lasting on average 94 minutes (standard deviation = 138; median = 60).
Discussion
This study suggested that TAPS therapy provided repeatable therapeutic benefit with a favorable safety profile over
three months of use in adults with ET. Despite the heterogeneity of ET presentation, the day-to-day symptomatic
variability of the disorder, and the variable therapeutic
needs of individual patients, the therapeutic response was
reproduced across multiple acute and longitudinal improvement measures, including clinician-rated TETRAS and CGI-I
scores, patient-rated BF-ADL, PGI-I, and quality of life scores
(Figures 2, 3 and 5), and objective accelerometer-measured
tremor power improvements (Figure 4).
The reductions in tremor and the absence of serious
device-related adverse events suggest that TAPS is a safe and
effective therapy option for ET. Over 50% of patients had a
≥2-fold reduction in tremor power with daily TAPS therapy (Figure 4D) and, for most (64%) patients, tremor relief
endured on average 90+ minutes following the therapy session. These tremor reductions are comparable to reductions
obtained with first-line pharmacotherapies propranolol and
primidone [17, 18]. While ET medications are effective in
approximately half of patients, their side effects at the doses
required to reduce tremor cause many patients to discontinue use [17, 18, 20–22]. This study did not find a relationship between concurrent ET medication usage and response
to TAPS therapy, but future work is needed to better understand the underlying patient characteristics and interactions
between multiple therapeutic approaches. Further, around
one in four patients in our study experienced tremor reduction
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similar to the 55–90% tremor reduction reported for invasive surgical therapies including DBS and MRgFUS [17, 23].
Though highly effective, DBS poses a risk of serious adverse
events, can lead to dysarthria and dysphagia, and for some
patients can lose efficacy over time [23, 39, 40]. Advanced
age, cognitive impairment, and other health issues can limit
access to DBS [41, 42], and some patients discontinue DBS
therapy due to VIM DBS-related side effects [41]. MRgFUS also
carries risks of side effects, with gait ataxia, unsteadiness, and
hand ataxia as the most commonly reported AEs [23]. In a
small number of patients, these side-effects were found to be
irreversible. The TAPS therapy tested in this study was devoid
of device-related serious AEs, and all AEs were reversible with
small changes (e.g., lowering device stimulation level or topical, over-the-counter ointment) or no intervention, differentiating it from surgical and pharmacological treatments.
This study also demonstrated the benefits of adding
objective at-home accelerometer-based measure of tremor
physiology to standard in-clinic assessments. Consistent with
previous reports of sensor-based measurements [43–45],
this study’s accelerometer-based measurements of tremor
power were correlated with gold-standard clinician-ratings
(Figure 4B). While the improvements in TETRAS and BF-ADL
scores quantified treatment efficacy for each patient at three
instances over the three-month study duration, the accelerometer-based metrics quantified treatment efficacy for, on
average, 113 therapy sessions per patient (21,806 sessions
for 193 patients). The objectivity and frequency of these
sensor-based measurements overcome key limitations of
previous single-session stimulation studies [28, 29]. These
data demonstrate how wearable technologies can enable
out-of-clinic remote monitoring of tremor and can be used
to identify whether a treatment remains effective over longitudinal use [44, 45]. Future work that expands remote tremor
physiology assessment to remove the inconvenience of performing postural holds and to develop metrics that quantify
functional ability throughout the day would benefit the field.
This study had a few important limitations that should be
considered while interpreting its results. First, the open-label, single-arm design limits conclusions reliant on assessment of longitudinal repeated-use sham response. A previous
23-patient blinded, randomized single-session trial using an
earlier version of TAPS therapy showed that TETRAS spiral
drawing scores had greater improvements with TAPS therapy
compared to sham [28]. A similarly constructed multi-site
trial with 77 patients did not reproduce this spiral drawing
finding, but found that TAPS therapy resulted in greater
improvements compared to sham in the TETRAS scores
summed for a lateral postural hold, forward outstretched
postural hold, and kinetic finger-nose-finger testing, and
improvements in tremor amplitude [29]. However, the latter
study’s blinding index of 0.608 [46] suggested it would be
challenging to successfully maintain a blind over months of
at-home usage. An active sham with altered parameters such
as a different stimulation bursting frequency or vibrotactile sensory stimulation could be considered; however, such
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designs risk activating neural circuitry via alternate pathways
and may not provide a true, treatment-free control. Future
research to establish robust methods to longitudinally maintain a patient blind for peripheral neuromodulation therapies would be a valuable asset for assessing novel therapies.
A sham arm could have also controlled for any improvements due to learning effects as patients grew more comfortable with performing the various tremor tasks. For example,
this study found pre-stimulation TETRAS and BF-ADL ratings
at Visit 3 were lower than pre-stimulation ratings at Visit 1,
which may be partially attributable to learning effects. A posthoc secondary endpoint analysis that segmented the at-home
data into the first, second, and third months of the trial found
that acute therapeutic efficacy was similar over time (median
improvement ratios of 2.0 in month 1, 2.3 in month 2; and
2.0 in month 3), and substantially greater than the improvement in median pre-stimulation tremor power from month
1 to month 3 (improvement ratio of 1.1). The consistency of
response over the three months at home suggests a reproducible therapeutic effect even with task-learning effects. It is
possible the cumulative reduction in baseline tremor severity may also be partially attributable to neurophysiological
remodeling resulting from repeated use of TAPS therapy.
Future studies on longitudinal mechanisms of action of this
therapy could be valuable to understand this contribution.
Second, clinical raters were unblinded to the study’s design,
which may have introduced bias into the TETRAS ratings, e.g.,
from pre- to post-stimulation at each of the three in-clinic
visits. Encouragingly, the objective tremor measurements
at the in-clinic visits showed that tremor power decreased
with stimulation (median improvement ratio of 1.7 at Visits
1 and 3) and that this decrease was directionally consistent with reductions in clinical TETRAS ratings (Figure 4D).
The confounding effect of rater-bias could be addressed by
using central ratings blinded to the study timepoints. While
TETRAS rating by video has been validated [47] and successfully used in some acute studies evaluating ET therapies [28,
29], a recent study on non-invasive pharmacologic therapy
suggested methodological concerns with central ratings [48].
Third, while the study found statistically significant
reductions across all tremor subtasks in both the TETRAS
and BF-ADL ratings, in part due to the study’s unprecedented sample size, the magnitude of those reductions varied between tasks (Table 3, Supplemental Table 1). Across
tasks, there were 20–40% of patients for whom TAPS therapy did not relieve specific tremor symptoms. We expect
there are two main reasons driving the observed variability
in individual and population-level response. Latent patient
subtypes may influence the variable treatment response
observed with all current ET therapies (i.e., pharmacotherapy, invasive therapy (DBS, MRgFUS), and non-invasive TAPS
therapy). While there is general consensus on the existence
of these subtypes [49] (e.g., early-onset vs late-onset ET), the
full range of sub-types, their clinical presentation, and their
interaction with therapeutic interventions has not been
fully characterized [50].
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Similarly, patients in this study had diverse symptomatic
presentations of tremor. We do not expect TAPS therapy to
improve tremor rating in a task that did not elicit tremor
for that patient, which creates a ceiling on maximum
improvement for that patient and accordingly lowers population-level average improvements. To our knowledge there
are no defined standards for what constitutes a clinically
meaningful improvement in TETRAS or BF-ADL, though the
resolution of the scales (0.5 or 1 point, depending on the
scale and task) [32, 33] and the community characterization
of intra- and inter-rater reliability for these scales [51, 52]
suggests that minimum detectable improvement thresholds
defined by the scale’s resolution can be considered clinically meaningful. Encouragingly, tremor improvements in
this study were larger and consistently on the order of the
task-specific minimum detectable improvements for the
subsets of patient who had baseline tremor (i.e., at least a
“Mild” tremor) in a given subtask (Table 3).
Finally, the pre-specified primary and secondary endpoints in this study excluded the fifty-eight patients who
exited the study early and therefore did not qualify for the
pre-specified analyses, which may have biased the study’s
reported responder rates. Fourteen of these 58 patients
cited “lack of device benefit” as the reason for withdrawal
of consent. A worst-case analysis treating these 14 patients
as “non-responders” would lower this study’s reported
responder rates by less than 5%. However, a post-hoc analysis found improvements in TETRAS and BF-ADL were
not statistically different between those that completed
the study, those withdrew citing lack of benefit, and those
that withdrew citing other reasons (e.g., adverse events,
time commitment; Supplemental Figure 3A). Likewise,
these patients’ median at-home improvement ratios were
comparable (Supplemental Figure 3B). The similarity in
response across these three patient cohorts suggests that
the study reflected the expected range of therapeutic
responses in the ET patient population; and the variability in patient perception despite the similar measured
response profiles highlights opportunities for the field to
continue developing patient-centered metrics of meaningful therapeutic improvement.
In conclusion, this study suggests that TAPS therapy is
safe and improves hand tremor and quality of life over three
months of use in a large cohort of patients with ET. Future
work examining how these clinical trial results translate into
the real-world setting would be valuable.
Additional Files
The additional files for this article can be found as follows:
• Supplemental Figure 1. Distribution of adherence
to prescribed sessions. DOI: https://doi.org/10.5334/
tohm.59.s1
• Supplemental Figure 2. Distribution of co-primary
tremor rating improvements. DOI: https://doi.
org/10.5334/tohm.59.s2
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• Supplemental Figure 3. Comparison between patients
who completed study (n = 205) and patients who withdrew citing lack benefit (n = 14) or other reasons (n =
44). DOI: https://doi.org/10.5334/tohm.59.s3
• Supplemental Table 1. Co-primary outcomes by task
for full study population compared to patient subgroups
with at least mild tremor power task. DOI: https://doi.
org/10.5334/tohm.59.s4
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